Olanzapine (CAS 132539-06-1) — formula C17H20N4S, molecular weight 312.4; category organic chemicals.
| CAS Number | 132539-06-1 |
|---|---|
| Molecular Formula | C17H20N4S |
| Molecular Weight | 312.4 |
| Melting Point | 189-195 °C |
| Boiling Point | 476 |
| LogP | 4.094 |
| Applications | Uses: THERAPEUTIC CATEGORY: Antipsychotic, Antiemetic, Antipsychotic Agent, Serotonin Uptake Inhibitor, MEDICATION, Use (kg) in Switzerland (2009): >50, Use (kg, approx.) in Germany (2009): >250, Use (kg) in USA (2002): 1950, Consumption (g per capita) in Switzerland (2009): 0.0064, Consumption (g per capita, approx.) in Germany (2009): 0.0031, Consumption (g per capita) in the USA (2002): 0.0069, Excretion rate: 1, Calculated removal (%): 14.6, For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients., Use Classification: Pharmaceuticals, Methods of Manufacturing: A mixture of sulfur, propanol, DMF, and trimethylamine are heated during the addition of malononitrile to produce 2-amino-5-methylthiophene-3-carbonitrile. Reaction of this compound with 2-fluoronitrobenzene and sodium hydride form 2-(2-nitroanilino)-5-methylthiophene-3-carbonitrile, which is subsequently treated with anhydrous stannous chloride to close the diazepine ring. The diazepine with 1-methylpiperazine in DMSO yields the product (base)., Preparation: J. K. Chakrabarti et al., European Patent Office 454436, eidem, United States of America patent 5229382 (1991, 1993 both to Lilly), Formulations, Preparations: Table: Olanzapine Preparations [Table#8116], Table: Olanzapine Combination Preparations [Table#8117] |
| Category | Organic Chemicals |
Documented applications: Uses: THERAPEUTIC CATEGORY: Antipsychotic, Antiemetic, Antipsychotic Agent, Serotonin Uptake Inhibitor, MEDICATION, Use (kg) in Switzerland (2009): >50, Use (kg, approx.) in Germany (2009): >250, Use (kg) in USA (2002): 1950, Consumption (g per capita) in Switzerland (2009): 0.0064, Consumption (g per capita, approx.) in Germany (2009): 0.0031, Consumption (g per capita) in the USA (2002): 0.0069, Excretion rate: 1, Calculated removal (%): 14.6, For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients., Use Classification: Pharmaceuticals, Methods of Manufacturing: A mixture of sulfur, propanol, DMF, and trimethylamine are heated during the addition of malononitrile to produce 2-amino-5-methylthiophene-3-carbonitrile. Reaction of this compound with 2-fluoronitrobenzene and sodium hydride form 2-(2-nitroanilino)-5-methylthiophene-3-carbonitrile, which is subsequently treated with anhydrous stannous chloride to close the diazepine ring. The diazepine with 1-methylpiperazine in DMSO yields the product (base)., Preparation: J. K. Chakrabarti et al., European Patent Office 454436, eidem, United States of America patent 5229382 (1991, 1993 both to Lilly), Formulations, Preparations: Table: Olanzapine Preparations [Table#8116], Table: Olanzapine Combination Preparations [Table#8117].
Olanzapine is a carbon-based organic compound with CAS registry number 132539-06-1 and molecular formula C17H20N4S (molecular weight 312.4), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 132539-06-1
Its molecular formula C17H20N4S comprises 17 C, 20 H, 4 N, 1 S atoms.
Also known as: Olanzapine · 奥氮平
Category: organic chemicals
The CAS registry number of Olanzapine is 132539-06-1.
Molecular formula C17H20N4S, molecular weight 312.4.
It is also registered under: Olanzapine, 奥氮平.
Recorded applications: Uses: THERAPEUTIC CATEGORY: Antipsychotic, Antiemetic, Antipsychotic Agent, Serotonin Uptake Inhibitor, MEDICATION, Use (kg) in Switzerland (2009): >50, Use (kg, approx.) in Germany (2009): >250, Use (kg) in USA (2002): 1950, Consumption (g per capita) in Switzerland (2009): 0.0064, Consumption (g per capita, approx.) in Germany (2009): 0.0031, Consumption (g per capita) in the USA (2002): 0.0069, Excretion rate: 1, Calculated removal (%): 14.6, For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients., Use Classification: Pharmaceuticals, Methods of Manufacturing: A mixture of sulfur, propanol, DMF, and trimethylamine are heated during the addition of malononitrile to produce 2-amino-5-methylthiophene-3-carbonitrile. Reaction of this compound with 2-fluoronitrobenzene and sodium hydride form 2-(2-nitroanilino)-5-methylthiophene-3-carbonitrile, which is subsequently treated with anhydrous stannous chloride to close the diazepine ring. The diazepine with 1-methylpiperazine in DMSO yields the product (base)., Preparation: J. K. Chakrabarti et al., European Patent Office 454436, eidem, United States of America patent 5229382 (1991, 1993 both to Lilly), Formulations, Preparations: Table: Olanzapine Preparations [Table#8116], Table: Olanzapine Combination Preparations [Table#8117].
Category: Organic Chemicals.
Independent reference data for Olanzapine (CAS 132539-06-1), compiled from public chemistry databases.
| CAS Registry Number | 132539-06-1 |
|---|---|
| PubChem CID | 135398745 |
| Molecular formula | C17H20N4S |
| IUPAC name | 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine |
| UNII (FDA) | N7U69T4SZR |
| Molecular Weight | 312.4 |
|---|---|
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 312.14086783 |
| Monoisotopic Mass | 312.14086783 |
| Topological Polar Surface Area | 59.1 |
| Heavy Atom Count | 22 |
| Boiling Point | 476 |
|---|---|
| Melting Point | 189-195 °C |
| Melting Point | 195 °C |
| LogP | 4.094 |
| LogP | log Kow = 3.00 |
| LogP | 3.0 |
| Dissociation Constants | 7.8 |
| Dissociation Constants | 10.57 |
| Collision Cross Section | 175.78 Ų [M+H]+ |
olanzapine; 132539-06-1; Olansek; Zyprexa Zydis; Zalasta; Zyprexa Velotab; Zyprexa Intramuscular; olanzapina; Olanzapine Mylan; LY-170053; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olazax; Olanzapine Teva; Olazax Disperzi; Olanzapine Glenmark
| Reported hazard statements | H301 (31.1%), H315 (75.4%), H317 (26.2%), H319 (91.8%), H336 (16.4%), H373 (16.4%) |
|---|
H301 (31.1%): Toxic if swallowed [Danger Acute toxicity, oral]
H315 (75.4%): Causes skin irritation [Warning Skin corrosion/irritation]
Olanzapine · CAS 132539-06-1 · C17H20N4S. UNII N7U69T4SZR. Boiling Point: 476; Melting Point: 189-195 °C; Melting Point: 195 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 奥氮平